Lung Cancer Research Review, Issue 74
In this issue:
Tarlatamab for previously treated SCLC
Osimertinib ± chemotherapy in EGFR-mutated advanced NSCLC
First-line selpercatinib vs. chemotherapy (±pembrolizumab) in RET fusion+ NSCLC
Adding pembrolizumab to chemotherapy in advanced pleural mesothelioma
Adding berzosertib to topotecan for relapsed SCLC
Patritumab deruxtecan for EGFR-mutated NSCLC after EGFR-TKI and platinum
Durvalumab after radiation for chemoradiotherapy-ineligible stage III NSCLC
Bintrafusp alfa vs. pembrolizumab in treatment-naive, PDL1-high advanced NSCLC
Brigatinib vs. alectinib in ALK-positive NSCLC after progression on crizotinib
First-line osimertinib for advanced EGFR-mutated NSCLC in the elderly
Expert contributor
Dr Divyanshu (Divy) Dua
Dr. Divyanshu “Divy” Dua graduated from the Manipal Academy of Higher Education, India followed by fellowship of Royal Australasian College of Physicians. He trained in internal medicine and medical oncology in Australia followed by clinical fellowship in drug development, early phase trials and thoracic malignancies at the Guys Hospital in London as well as Sarah […]
Latest Publications and Videos
Stay up to date with our latest clinical information.
Explore Research Review Publications and Videos
Dive into our publications and videos content from over 50 areas of medicine including Cardiology, Diabetes, Oncology, Haematology and Psychiatry.
Terms and Conditions
Website terms of use
By using our website, you agree to follow these terms and conditions.
Privacy policy
We take your privacy seriously. To understand how we collect, use, and protect your information, please read our Privacy Policy, which is part of these terms.
Copyright and use of website content
The content of our website is protected by copyright, trademarks, and other legal rights. You can: view, download, or print a single copy of content for your personal or professional use.
You cannot: copy, modify, or distribute website content, or use our website content for commercial purposes or in other works without permission.
Links to third-party websites
The Research Review website may link to third-party websites for your convenience. However:
We do not endorse or approve their products, services, or actions.
We are not responsible for their content or how they operate.
There is no formal partnership between us and third parties unless we clearly state otherwise.
Disclaimer and limitation of liability
We do our best to keep the information on our website accurate, but we do not guarantee that it is always correct or up to date.
To the fullest extent allowed by law, we are not responsible for:
Any loss, damage, or costs you may suffer from using (or being unable to use) our website.
Any decisions you make based on the information provided.
Any business losses, such as lost profits, lost data, or business interruptions.
Governing law
These terms are governed by New Zealand law. If there is a dispute, it must be resolved in a New Zealand court.